EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas

Konstantinos Vazaios iD, Patricia Hernández López, Tineke Aarts-Riemens, Annet Daudeij, Vera Kemp iD, Rob C Hoeben iD, Trudy Straetemans, Esther Hulleman iD, Friso G Calkoen iD, Jasper van der Lugt iD, Jürgen Kuball iD

International Journal of Molecular Sciences · 2025-02-28 · 26 (5) · 2167

DOI: 10.3390/ijms26052167 ↗

At a glance

Journal article in International Journal of Molecular Sciences, published online on 2025-02-28. Written by Konstantinos Vazaios and 10 co-authors. Institution: Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands. Major MEDLINE topics: Glioma, Oncolytic Virotherapy, Oncolytic Viruses, Receptors, Antigen, T-Cell, gamma-delta. Cited 6 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY 4.0). Funded by: Inspire2live, Choir4hope, Princess Maxima Foundation.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Due to the minimal survival benefits of existing therapies for pediatric diffuse midline glioma (DMG) patients, new therapeutic modalities are being investigated. Immunotherapies such as CAR-T cells and oncolytic viruses (OVs) are part of these efforts, as evidenced by the increasing number of clinical trials. αβ T cells engineered with a high-affinity γ9δ2 T-cell receptor (TEGs) are immune cells designed to target metabolic changes in malignant or virally infected cells via BTN2A1 and BTN3A. Because the expression of BTN2A1 and BTN3A can be altered in tumor and infected cells, combining TEGs and OVs could potentially enhance the anti-tumor response. We investigated this hypothesis in the following study. We demonstrate that TEGs can indeed target DMG, which expresses BTN2A1 and BTN3A at varying levels, and that OVs can further enhance the expression of BTN3A—but not BTN2A1—in DMG. Functionally, TEGs killed DMG cell cultures, and this killing was further increased after OV infection of the DMGs with either adenovirus Δ24-RGD or reovirus R124 under suboptimal conditions. However, this additive effect was lost when γ9δ2 TCR–ligand interaction was boosted by pamidronate. This study demonstrates the additive effect of combining OVs and Vγ9Vδ2 TCR-engineered immune cells under suboptimal conditions and supports a combination strategy to enhance the efficacy of both therapeutic modalities.

Subjects

MeSH terms (MEDLINE)

GliomaOncolytic VirotherapyOncolytic VirusesReceptors, Antigen, T-Cell, gamma-deltaImmunotherapy, AdoptiveT-LymphocytesBrain NeoplasmsHumansCell Line, TumorCombined Modality Therapy

Author keywords

?9?2TCRD24-RGDR124TEGsdiffuse midline gliomaimmune-oncologyimmunotherapyoncolytic viruses

Substances

Receptors, Antigen, T-Cell, gamma-delta

Authors and institutions

  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands.
  • Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden University, 2333 ZC Leiden, The Netherlands.
  • Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.

ORCID profiles: Konstantinos Vazaios, Vera Kemp, Rob C Hoeben, Esther Hulleman, Friso G Calkoen, Jasper van der Lugt, Jürgen Kuball

Funding

  • Inspire2live
  • Choir4hope
  • Princess Maxima Foundation
  • KWF 12586, 13043, 13493, 15614, 15570
  • Oncode Accelerator
  • Dutch Research Council
  • Dutch Foundation

Cite

APA

Vazaios, K., Hernández López, P., Aarts-Riemens, T., Daudeij, A., Kemp, V., Hoeben, R. C., Straetemans, T., Hulleman, E., Calkoen, F. G., van der Lugt, J., & Kuball, J. (2025). Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas. International Journal of Molecular Sciences, 26(5), 2167. https://doi.org/10.3390/ijms26052167

Vancouver

Vazaios K, Hernández López P, Aarts-Riemens T, Daudeij A, Kemp V, Hoeben RC, et al. Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas. International Journal of Molecular Sciences. 2025;26(5):2167. doi:10.3390/ijms26052167

BibTeX
@article{Vazaios2025,
  author = {Vazaios, Konstantinos and Hernández López, Patricia and Aarts-Riemens, Tineke and Daudeij, Annet and Kemp, Vera and Hoeben, Rob C and Straetemans, Trudy and Hulleman, Esther and Calkoen, Friso G and van der Lugt, Jasper and Kuball, Jürgen},
  title = {Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {5},
  pages = {2167},
  doi = {10.3390/ijms26052167}
}
Start for free →